高危因素鼻咽癌调强放疗中不照射Ib区与照射Ib区的倾向性评分匹配队列研究
本研究纳入2009至2012年间接受调强放疗的443例影像学结外侵犯(rENE)或II区淋巴结最大轴径(MAD)≥20 mm的鼻咽癌患者,经倾向性评分匹配(PSM)后比较不照射与照射Ib区的疗效。匹配后169对患者中,Ib区失败率两组分别为1.8%与1.2%(P>0.999),5年区域无复发生存率分别为88.4%与92.6%,各项生存指标两组相似;照射Ib区组5年后≥1级口干发生率更高(27.5% vs 16.5%,P=0.029)。作者认为,在Ib区淋巴结阴性且伴rENE或II区MAD≥20 mm的鼻咽癌患者中,不照射Ib区似乎安全可行,且口干症状更少。
要点
- 匹配后不照射Ib区组与照射Ib区组的Ib区失败率分别为1.8%与1.2%(P>0.999)。
- 两组5年区域无复发生存率分别为88.4%与92.6%,RRFS的HR为1.508(95%CI 0.762-2.986,P=0.239)。
- 照射Ib区组5年后≥1级口干发生率高于不照射组(27.5% vs 16.5%,P=0.029)。
核心结论
- 在Ib区淋巴结阴性且伴rENE或II区MAD≥20 mm的鼻咽癌患者中,不照射颈部Ib区似乎安全可行。
- 与照射颈部Ib区相比,不照射Ib区可减少口干症状。
研究设计与样本
- 研究纳入2009至2012年间接受调强放疗的443例伴rENE或II区淋巴结MAD≥20 mm的鼻咽癌患者。
- 采用倾向性评分匹配平衡年龄、性别、T和N分期、治疗前EBV DNA水平及II区rENE和MAD等预后因素。
- 匹配后形成169对患者,中位随访119个月,采用Kaplan-Meier分析和log-rank检验比较区域生存结局。
主要发现
- 匹配队列中不照射Ib区组与照射Ib区组的Ib区失败分别为3/169(1.8%)与2/169(1.2%),P>0.999。
- 两组5年区域无复发生存率分别为88.4%与92.6%。
- 匹配后RRFS的HR为1.508(95%CI 0.762-2.986,P=0.239),OS的HR为1.219(95%CI 0.754-1.972,P=0.418),DMFS的HR为1.605(95%CI 0.900-2.863,P=0.109),LRFS的HR为0.956(95%CI 0.436-2.095,P=0.910),两组相似。
- 照射Ib区组5年后≥1级口干发生率高于不照射Ib区组(27.5% vs 16.5%,P=0.029)。
- 两组3-4级晚期毒性发生率相似。
关键数值与推荐
- 高危因素定义为影像学结外侵犯(rENE)或II区淋巴结最大轴径(MAD)≥20 mm。
- 不照射Ib区组与照射Ib区组的Ib区失败率分别为1.8%与1.2%(P>0.999)。
- 两组5年区域无复发生存率分别为88.4%与92.6%。
- 照射Ib区组5年后≥1级口干发生率为27.5%,不照射Ib区组为16.5%(P=0.029)。
临床怎么用
- 作者认为,对Ib区淋巴结阴性且伴rENE或II区MAD≥20 mm的鼻咽癌患者,不照射颈部Ib区似乎安全可行。
- 与照射颈部Ib区相比,不照射Ib区可减少口干症状。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIM: Level Ib lymph nodes metastasis is rare in nasopharyngeal carcinoma (NPC). We aimed to evaluate the feasibility of sparing level Ib-irradiation in NPC patients with high-risk factors. MATERIALS AND METHODS: Four hundred forty-three NPC patients with radiologic extranodal extension (rENE) or level II lymph node maximal axial diameter (MAD) ≥ 20 mm treated by intensity-modulated radiotherapy (IMRT) between 2009 and 2012 were included in this study. Propensity score matching (PSM) was applied to balance potential prognostic factors (including age, sex, T and N stage, pretreatment EBV DNA level, and level II rENE and MAD) between patients who received and omitted level Ib irradiation. Kaplan-Meier analysis and the log-rank test were used to compare regional survival outcomes. RESULTS: PSM resulted in 169 matched pairs of eligible patients. The median follow-up period was 119 months in the matched cohort. The number of level Ib failure in the level Ib-sparing and level-Ib irradiation groups were 3/169 (1.8 %) vs 2/169 (1.2 %), P > 0.999. And the 5-year regional relapse-free survival (RRFS) rates of the two groups were 88.4 % vs 92.6 %, respectively. After PSM, RRFS (hazard ratio [HR]: 1.508, 95 % confidence interval [CI]: 0.762-2.986, P = 0.239), OS (HR: 1.219, 95 % CI: 0.754-1.972, P = 0.418), distant metastasis-free survival (DMFS) (HR: 1.605, 95 % CI: 0.900-2.863, P = 0.109), and local relapse-free (LRFS) (HR: 0.956, 95 % CI: 0.436-2.095, P = 0.910) were similar in the two arms. The incidence of grade ≥ 1 dry mouth after 5 years was higher in the level Ib-irradiation group (27.5 % vs 16.5 %, P = 0.029). However, the incidences of grade 3-4 late toxicities were similar between the two groups. CONCLUSION: Neck level Ib-sparing appears to be safe and feasible in NPC patients with rENE or level II MAD ≥ 20 mm and negative level Ib lymph nodes. Compared with cervical level Ib-irradiation, omission of irradiation to level Ib provides less dry mouth symptom.
引用
- Wang G, Huang C, Yang K, et al. Neck level Ib-sparing versus level Ib-irradiation in intensity-modulated radiotherapy for the treatment of nasopharyngeal carcinoma with high-risk factors: A propensity score-matched cohort study. Radiother Oncol. 2022. PMID: 36375564. doi:10.1016/j.radonc.2022.11.005
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。